Lupin appoints Mark D McDade as new Independent Director

Published On 2021-02-02 10:30 GMT   |   Update On 2021-02-02 10:33 GMT

Mumbai: Pharma major, Lupin Limited, announced the appointment of Mr. Mark D. McDade as an Independent Director effective January 28, 2021. Mr. McDade is the co-Founder and Partner at Qiming Venture Partners, USA where he led several high-value investments in biotherapeutics, including cell and gene therapy and digital health. With a career spanning over 37 years, he has led and...

Login or Register to read the full article

Mumbai: Pharma major, Lupin Limited, announced the appointment of Mr. Mark D. McDade as an Independent Director effective January 28, 2021. 

Mr. McDade is the co-Founder and Partner at Qiming Venture Partners, USA where he led several high-value investments in biotherapeutics, including cell and gene therapy and digital health. With a career spanning over 37 years, he has led and transformed global companies as well as founded and advanced Biotech companies.

Commenting on the appointment, Manju D. Gupta, Chairman, Lupin said, "We are delighted to welcome Mr. Mark D. McDade on Lupin's board. We are confident that his diverse experience across large, mid and development-stage companies across Specialty & Biologics, will help advance our growth journey."
Mr. McDade holds a B.A. in History from Dartmouth College and MBA from Harvard Business School.
Lupin Limited is a global pharmaceutical company based in Mumbai, Maharashtra, India.

The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle-East regions.





Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News